On April 25, 2025, Foghorn Therapeutics appointed Stuart Duty and Dr. Neil J. Gallagher as independent directors, effective May 1, 2025, each receiving stock options and cash retainers for their service. The appointments ensure compliance with Nasdaq's audit committee requirements.